

Matthew W Jenner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7284378/publications.pdf>

Version: 2024-02-01

73
papers

2,650
citations

236612

25
h-index

189595

50
g-index

73
all docs

73
docs citations

73
times ranked

3306
citing authors

#	ARTICLE	IF	CITATIONS
1	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
2	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. <i>Journal of Clinical Oncology</i> , 2022, 40, 2889-2900.	0.8	29
3	Intensity-adjusted therapy in transplant-ineligible patients with newly diagnosed Multiple Myeloma (FITNESS (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. <i>BMJ Open</i> , 2022, 12, e056147.	0.8	11
4	Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , 2021, 35, 2043-2053.	3.3	23
5	Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 551-555.	1.2	25
6	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , 2021, 192, 853-868.	1.2	14
7	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	0.6	49
8	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003454.	3.9	18
9	MUK-nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. <i>BMI Open</i> , 2021, 11, e046225.	0.8	18
10	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 154-161.e3.	0.2	11
11	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 667-675.	0.2	12
12	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 1328-1341.	1.3	2
13	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. <i>Leukemia</i> , 2020, 34, 604-612.	3.3	56
14	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	1.7	16
15	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. <i>Leukemia</i> , 2020, 34, 3091-3096.	3.3	26
16	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	3.3	55
17	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , 2020, 136, 1091-1104.	0.6	58
18	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. <i>Haematologica</i> , 2020, Online ahead of print, 0-0.	1.7	16

#	ARTICLE	IF	CITATIONS
19	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e616-e629.	2.2	42
20	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1617-1628.	0.8	24
21	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 57-73.	5.1	245
22	A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results. <i>Blood</i> , 2019, 134, 1890-1890.	0.6	5
23	Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance. <i>Blood</i> , 2019, 134, 3132-3132.	0.6	1
24	Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimism Trial By Patient Age and Prior Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3120-3120.	0.6	1
25	Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. <i>Leukemia</i> , 2018, 32, 102-110.	3.3	177
26	Subclonal TP53 copy number is associated with prognosis in multiple myeloma. <i>Blood</i> , 2018, 132, 2465-2469.	0.6	29
27	Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic ERCC6L2 variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7777-7782.	3.3	37
28	Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimism Trial. <i>Blood</i> , 2018, 132, 3278-3278.	0.6	5
29	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2018, 132, 1994-1994.	0.6	10
30	Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multicentre UK experience. <i>British Journal of Haematology</i> , 2017, 176, 908-917.	1.2	25
31	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	3.3	98
32	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. <i>Blood Cancer Journal</i> , 2016, 6, e506-e506.	2.8	68
33	The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM). <i>Blood</i> , 2016, 128, 4412-4412.	0.6	2
34	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1021-1032.	2.0	27
35	Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients. <i>Blood</i> , 2015, 126, 189-189.	0.6	4
36	Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial. <i>Blood</i> , 2015, 126, 1852-1852.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Updates to the guidelines for the diagnosis and management of multiple myeloma. British Journal of Haematology, 2014, 167, 131-133.	1.2	20
38	Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. British Journal of Haematology, 2013, 162, 107-111.	1.2	50
39	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 2010, 116, e56-e65.	0.6	315
40	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology, 2010, 150, 326-333.	1.2	57
41	Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clinical Cancer Research, 2010, 16, 1856-1864.	3.2	124
42	Liposomal cytarabine in cerebrospinal fluid. British Journal of Haematology, 2009, 145, 679-679.	1.2	3
43	MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica, 2009, 94, 78-86.	1.7	106
44	Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. European Journal of Haematology, 2008, 81, 432-436.	1.1	16
45	Deletions of <i>CDKN2C</i> in Multiple Myeloma: Biological and Clinical Implications. Clinical Cancer Research, 2008, 14, 6033-6041.	3.2	88
46	CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma. Blood, 2008, 112, 3707-3707.	0.6	4
47	The Impact of Constitutional Copy Number Variants in Myeloma. Blood, 2008, 112, 496-496.	0.6	1
48	Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling Identifies Kinase Pathway Alterations.. Blood, 2008, 112, 1694-1694.	0.6	0
49	High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma. Blood, 2008, 112, 625-625.	0.6	0
50	XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.. Blood, 2008, 112, 1686-1686.	0.6	0
51	Homozygous Deletions Can Be Used to Define a Cell Death Specific Gene Expression Signature Able to Predict Outcome in Myeloma. Blood, 2008, 112, 2725-2725.	0.6	0
52	The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica, 2007, 92, 1149-1150.	1.7	71
53	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood, 2007, 110, 3291-3300.	0.6	133
54	Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. British Journal of Haematology, 2007, 137, 268-269.	1.2	96

#	ARTICLE	IF	CITATIONS
55	Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.. Blood, 2007, 110, 3593-3593.	0.6	33
56	Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.. Blood, 2007, 110, 395-395.	0.6	1
57	The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients.. Blood, 2007, 110, 2727-2727.	0.6	8
58	Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.. Blood, 2007, 110, 4841-4841.	0.6	0
59	Genome-Wide Identification of Gene Expression Networks Affected by Genomic Changes in Multiple Myeloma.. Blood, 2007, 110, 2494-2494.	0.6	4
60	Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.. Blood, 2007, 110, 2473-2473.	0.6	0
61	Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.. Blood, 2007, 110, 2474-2474.	0.6	0
62	An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.. Blood, 2007, 110, 2493-2493.	0.6	0
63	The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide + vincristine + doxorubicin + methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leukemia and Lymphoma. 2006, 47, 2335-2338.	0.6	43
64	Advances in oral therapy for multiple myeloma. Lancet Oncology, The, 2006, 7, 316-325.	5.1	42
65	Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood, 2006, 108, 1733-1743.	0.6	176
66	Fine Mapping and Expression Analysis of Chromosome 1 with the Aim of Defining Critically Deregulated Genes Important in the Pathogenesis of Myeloma.. Blood, 2006, 108, 112-112.	0.6	2
67	The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).. Blood, 2006, 108, 3537-3537.	0.6	6
68	Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.. Blood, 2006, 108, 3555-3555.	0.6	2
69	Abnormalities of 16q in Multiple Myeloma Are Associated with Poor Prognosis: 500K Gene Mapping and Expression Correlations Identify Two Potential Tumor Suppressor Genes, WWOX and CYLD.. Blood, 2006, 108, 110-110.	0.6	1
70	Sub-Classification of Hyperdiploid Myeloma Using Global Gene Expression Profiling and SNP-Based Mapping Arrays.. Blood, 2006, 108, 3390-3390.	0.6	0
71	Insights into the Basis of Chromosomal Imbalances during the Clonal Evolution of Multiple Myeloma Using SNP Array Analysis.. Blood, 2005, 106, 621-621.	0.6	0
72	Identification of Collaborating Oncogenic Events Leading to Disease Progression in Myeloma Cases with a t(4;14) and t(11;14) Using SNP and Gene Expression Arrays.. Blood, 2005, 106, 1542-1542.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Status of Chromosome 13 in Multiple Myeloma: Integrated Approach Using SNP Mapping Array and Gene Expression Array.. Blood, 2005, 106, 1563-1563.	0.6	0